1. Scrip

Pneumococcal Vaccines Market Snapshot: Pfizer And Merck Face Off

 
• By Jessica Merrill

Pfizer's Prevnar 20 and Merck's Vaxneuvance are launching simultaneously and are expected to help drive vaccines growth for both big pharmas.

hockey face off
Pfizer and Merck are facing off with new launches in pneumococcal vaccines • Source: Alamy

Pfizer Inc. and Merck & Co., Inc. both have a long heritage in the pneumococcal vaccines market and are simultaneously launching new offerings that are expected to deliver near- to mid-term vaccine franchise growth. With Pfizer's Prevnar 20 and Merck's Vaxneuvance, both companies are aiming to capture shares of the adult vaccine market, a big commercial opportunity though substantially smaller than the pediatric market.

ACIP Recommendations 
  • Prevnar 20 recommended for adults 65 and older and adults ages 19 to 64 with certain underlying medical conditions.
  • Vaxneuvance recommended for adults 65 and older and...

Now that the US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) has weighed in and updated its recommendations on pneumococcal vaccinations for adults, the commercial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.